Abhängigkeitsrisiko
Studienlage · Detail Narrative Review (Nature Reviews) · Abhängigkeitsrisiko · 2021

Cannabis use and cannabis use disorder

Gemischt 495 Zitate
StichprobeNarrative Review
Verblindungunklar
DesignNarrative Review (Nature Reviews)
Kernaussage

Psychosoziale Interventionen reduzieren Cannabis-Konsum wirksam, dauerhafte Abstinenz bleibt selten; keine zugelassene Pharmakotherapie verfügbar.

Zusammenfassung

Narrative Review (Nature Reviews) zu Cannabis Use Disorder (CUD): ~10% der 193 Millionen Cannabis-Nutzer weltweit entwickeln CUD; psychosoziale Therapien (CBT, MET, Contingency Management) reduzieren Konsum signifikant; keine zugelassenen Pharmakotherapien; Legalisierung kann CUD-Prävalenz durch Verfügbarkeit stärkerer Produkte erhöhen.

ZusammenfassungNarrativer Review zu Cannabis-Gebrauchsstörung (CUD): Etwa 10 % der weltweit 193 Millionen Cannabis-Konsumenten entwickeln eine CUD; psychosoziale Therapien (KVT, MET, Contingency Management) reduzieren den Konsum wirksam, jedoch ohne häufige dauerhafte Abstinenz; zugelassene Pharmakotherapien fehlen bislang.
Qualitätsprofil
Größe
Verblindung
Effektstärke Gemischt
Zitate / Jahr
Autoren
Connor J P, Stjepanović D, Le Foll B et al.
DOI 10.1038/s41572-021-00247-4
Design: Narrative Review (Nature Reviews)
Teilen
Abstract
Cannabis use disorder (CUD) is an underappreciated risk of using cannabis that affects ~10% of the 193 million cannabis users worldwide. The individual and public health burdens are less than those of other forms of drug use, but CUD accounts for a substantial proportion of persons seeking treatment for drug use disorders owing to the high global prevalence of cannabis use. Cognitive behavioural therapy, motivational enhancement therapy and contingency management can substantially reduce cannabis use and cannabis-related problems, but enduring abstinence is not a common outcome. No pharmacotherapies have been approved for cannabis use or CUD, although a number of drug classes (such as cannabinoid agonists) have shown promise and require more rigorous evaluation. Treatment of cannabis use and CUD is often complicated by comorbid mental health and other substance use disorders. The legalization of non-medical cannabis use in some high-income countries may increase the prevalence of CUD by making more potent cannabis products more readily available at a lower price. States that legalize medical and non-medical cannabis use should inform users about the risks of CUD and provide information on how to obtain assistance if they develop cannabis-related mental and/or physical health problems.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel